Dual checkpoint inhibitor-associated eosinophilic enteritis

Keyphrases

• Checkpoint Inhibitors 100%
• Eosinophilic Gastroenteritis 100%
• Immune Checkpoint Inhibitors 66%
• Inflammation 33%
• Treatment Response 33%
• Eosinophilia 33%
• Clinical Manifestations 33%
• Biological Effects 33%
• Associated Symptoms 33%
• Nivolumab 33%
• Ipilimumab 33%
• Immune-related Adverse Events 33%
• Hypereosinophilia 33%
• First Case Report 33%
• Rapid Resolution 33%
• Peripheral Eosinophilia 33%
• Advanced Cutaneous Melanoma 33%

Medicine and Dentistry

• Eosinophilic Enteritis 100%
• Eosinophilia 66%
• Treatment Response 33%
• Case Presentation 33%
• Ipilimumab 33%
• Nivolumab 33%
• Immune-Related Adverse Events 33%
• Hypereosinophilia 33%
• Melanoma Skin Cancer 33%
• Biological Activity 33%